After three years, 69% of those taking mitoxantrone had survived, compared with 45% of those given idarubicin.

BBC: Child leukaemia drug boosts survival rates

The study was stopped, and the children taking idarubicin were switched to mitoxantrone.

BBC: Child leukaemia drug boosts survival rates

An initial human test of the combo--chemotherapy drug idarubicin and Millennium Pharmaceuticals' multiple myeloma drug Velcade--is under way at the University of Kentucky.

FORBES: On The Cover/Top Stories